Total Payments
$101,267
2024 Payments
$4,400
Companies
51
Transactions
328
Medicare Patients
25,081
Medicare Billing
$5.1M
Payment Breakdown by Category
Consulting$51,309 (50.7%)
Other$33,092 (32.7%)
Travel$8,440 (8.3%)
Food & Beverage$8,078 (8.0%)
Education$346.90 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,309 | 21 | 50.7% |
| Honoraria | $30,642 | 26 | 30.3% |
| Travel and Lodging | $8,440 | 17 | 8.3% |
| Food and Beverage | $8,078 | 245 | 8.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,450 | 1 | 2.4% |
| Education | $346.90 | 7 | 0.3% |
| Unspecified | $0 | 11 | 0.0% |
Payments by Type
General
$101,267
317 transactions
Ownership
$0
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $35,269 | 45 | $0 (2024) |
| Daiichi Sankyo Inc. | $26,975 | 22 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $9,524 | 18 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $7,203 | 9 | $0 (2020) |
| Celgene Corporation | $6,994 | 15 | $0 (2024) |
| Exelixis Inc. | $2,565 | 3 | $0 (2019) |
| BeiGene USA, Inc. | $2,400 | 2 | $0 (2023) |
| Puma Biotechnology, Inc. | $1,637 | 9 | $0 (2023) |
| Coherus Biosciences Inc. | $1,088 | 1 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $1,050 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,400 | 61 | AstraZeneca Pharmaceuticals LP ($2,593) |
| 2023 | $27,168 | 76 | Cornerstone Specialty Network LLC ($17,897) |
| 2022 | $9,744 | 59 | Cornerstone Specialty Network LLC ($4,000) |
| 2021 | $5,936 | 20 | Cornerstone Specialty Network LLC ($4,500) |
| 2020 | $24,859 | 19 | Daiichi Sankyo Inc. ($22,042) |
| 2019 | $14,715 | 29 | Bayer HealthCare Pharmaceuticals Inc. ($5,403) |
| 2018 | $6,999 | 27 | Cornerstone Specialty Network LLC ($3,336) |
| 2017 | $7,447 | 37 | Celgene Corporation ($6,780) |
All Payment Transactions
328 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $32.39 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $33.66 | General |
| Category: Hematology | ||||||
| 12/04/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $20.96 | General |
| Category: Diagnostics | ||||||
| 12/03/2024 | Legend Biotech USA Inc. | CARVYKTI (Biological) | Education | In-kind items and services | $25.72 | General |
| Category: Oncology | ||||||
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,340.00 | General |
| 11/26/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Oncology | ||||||
| 11/22/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $28.84 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $34.17 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/08/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $20.80 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.97 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $27.03 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $25.79 | General |
| Category: Oncology | ||||||
| 10/18/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Oncology | ||||||
| 10/16/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Oncology | ||||||
| 10/15/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $34.32 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $32.51 | General |
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 10/02/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $43.90 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.58 | General |
| Category: Hematology | ||||||
| 08/09/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $25.37 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 3,891 | 155,048 | $3.9M | $893,339 |
| 2022 | 43 | 4,570 | 150,851 | $4.1M | $1.3M |
| 2021 | 61 | 8,210 | 196,917 | $4.2M | $1.5M |
| 2020 | 65 | 8,410 | 223,578 | $4.4M | $1.4M |
Total Patients
25,081
Total Services
726,394
Medicare Billing
$5.1M
Procedure Codes
207
All Medicare Procedures & Services
207 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 55 | 12,300 | $730,260 | $226,317 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 693 | 1,236 | $287,175 | $132,061 | 46.0% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 15 | 3,400 | $541,700 | $121,422 | 22.4% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 64 | 17,242 | $469,320 | $105,604 | 22.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 49 | 78,750 | $327,750 | $68,783 | 21.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 31 | 265 | $148,326 | $32,735 | 22.1% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 34 | 4,801 | $264,055 | $26,612 | 10.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 789 | 3,116 | $98,540 | $23,672 | 24.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 122 | 122 | $43,169 | $17,459 | 40.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 176 | 1,234 | $101,298 | $15,459 | 15.3% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 12 | 1,880 | $449,680 | $15,406 | 3.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 91 | 246 | $63,664 | $15,067 | 23.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 56 | 186 | $29,451 | $12,953 | 44.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 514 | 1,468 | $25,162 | $11,315 | 45.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 99 | $22,884 | $10,395 | 45.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 65 | $20,261 | $9,559 | 47.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 119 | $23,420 | $8,214 | 35.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 39 | 268 | $36,039 | $7,205 | 20.0% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 15 | 70 | $17,284 | $6,356 | 36.8% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 188 | $22,665 | $6,058 | 26.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 66 | $18,106 | $4,087 | 22.6% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 23 | 18,200 | $30,455 | $2,822 | 9.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 22 | 109 | $14,338 | $2,801 | 19.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 33 | 164 | $13,820 | $2,368 | 17.1% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2023 | 597 | 693 | $8,260 | $1,686 | 20.4% |
About Dr. Chitra Rajagopal, MD
Dr. Chitra Rajagopal, MD is a Hematology & Oncology healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467544312.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chitra Rajagopal, MD has received a total of $101,267 in payments from pharmaceutical and medical device companies, with $4,400 received in 2024. These payments were reported across 328 transactions from 51 companies. The most common payment nature is "Consulting Fee" ($51,309).
As a Medicare-enrolled provider, Rajagopal has provided services to 25,081 Medicare beneficiaries, totaling 726,394 services with total Medicare billing of $5.1M. Data is available for 4 years (2020–2023), covering 207 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Bethesda, MD
- Active Since 09/29/2006
- Last Updated 09/22/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1467544312
Products in Payments
- Enhertu (Drug) $22,145
- Revlimid (Drug) $6,802
- LYNPARZA (Drug) $5,853
- Nexavar (Drug) $5,403
- Cabometyx (Drug) $2,565
- BRUKINSA (Drug) $2,400
- Nerlynx (Drug) $1,555
- LIBTAYO (Biological) $1,050
- Stivarga (Drug) $900.00
- Vitrakvi (Drug) $900.00
- CALQUENCE (Drug) $756.05
- ENHERTU (Drug) $525.00
- TAGRISSO (Drug) $465.00
- IMBRUVICA (Drug) $424.42
- KEYTRUDA (Biological) $297.23
- SARCLISA (Biological) $294.40
- BOSULIF (Drug) $219.06
- Perjeta (Biological) $161.30
- XARELTO (Drug) $135.98
- DARZALEX (Biological) $130.25
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Bethesda
Sandra Swain, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Bruce Cheson, Md, MD
Hematology & Oncology — Payments: $665,051
Hematology & Oncology $665,051
Dr. Susan Leitman, M.d, M.D
Hematology & Oncology — Payments: $110,420
Hematology & Oncology $110,420
Phillip Scheinberg, M.d, M.D
Hematology & Oncology — Payments: $80,747
Hematology & Oncology $80,747
Gregory Frykman, M.d, M.D
Hematology & Oncology — Payments: $21,375
Hematology & Oncology $21,375
Dr. James Gulley, Md Phd Facp, MD PHD FACP
Hematology & Oncology — Payments: $11,595
Hematology & Oncology $11,595